Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All montelukast studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchMontelukastMontelukast (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Value of montelukast as a potential treatment of post-COVID-19 persistent cough: a non-randomized controlled pilot study

Mohamed Hussein et al., The Egyptian Journal of Bronchology, doi:10.1186/s43168-022-00154-6
Sep 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Improvement 50% Improvement Relative Risk Paroxysms/day 70% VAS 82% Severity index 80% QOL 82% Montelukast  Mohamed Hussein et al.  LATE TREATMENT  RCT Is late treatment with montelukast beneficial for COVID-19? RCT 68 patients in Egypt Improved recovery with montelukast (p<0.000001) c19early.org Mohamed Hussein et al., The Egyptian J.., Sep 2022 Favorsmontelukast Favorscontrol 0 0.5 1 1.5 2+
29th treatment shown to reduce risk in November 2021
 
*, now with p = 0.0045 from 8 studies.
Lower risk for mortality, hospitalization, and cases.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments. c19early.org
RCT 68 post-COVID-19 outpatients showing improvement in cough severity measures with montelukast treatment. The montelukast group had a greater reduction in number of cough paroxysms per day, cough severity visual analog scale, cough severity index, and improved cough quality of life scores compared to the control group. The montelukast group also had a shorter duration of cough.
improvement, 50.0% lower, relative time 0.50, p < 0.001, treatment mean 5.0 (±1.4) n=32, control mean 10.0 (±1.5) n=36.
paroxysms/day, 70.0% lower, relative time 0.30, p < 0.001, treatment mean 3.0 (±1.2) n=32, control mean 10.0 (±4.1) n=36.
VAS, 81.8% lower, relative time 0.18, p < 0.001, treatment mean 12.0 (±6.0) n=32, control mean 66.0 (±12.0) n=36.
severity index, 80.0% lower, relative time 0.20, p < 0.001, treatment mean 4.0 (±1.1) n=32, control mean 20.0 (±5.0) n=36.
QOL, 81.6% lower, relative time 0.18, p < 0.001, treatment mean 18.0 (±2.5) n=32, control mean 98.0 (±2.0) n=36.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Mohamed Hussein et al., 15 Sep 2022, Randomized Controlled Trial, Egypt, peer-reviewed, mean age 43.0, 7 authors, post-COVID cough. Contact: islamgalal76@yahoo.com (corresponding author).
This PaperMontelukastAll
Value of montelukast as a potential treatment of post-COVID-19 persistent cough: a non-randomized controlled pilot study
Aliae A R Mohamed Hussein, Mohamed Eltaher A A Ibrahim, Hoda A Makhlouf, Nahed A Makhlouf, Howaida K Abd-Elaal, Karima M S Kholief, Islam G Sayed
The Egyptian Journal of Bronchology, doi:10.1186/s43168-022-00154-6
Background: This pilot study included 68 cases with post-COVID-19 persistent cough (> 8 weeks), randomly allocated into two groups; intervention group (32 patients) received standard cough therapy, and montelukast 10 mg/ day for 14 days and control group (36 patients) received only cough sedatives. Results: We found a significant improvement in the number of cough paroxysms/day, cough severity visual analog scale, cough severity index and cough quality of life, shorter duration improvement, and minimal side effects in the interventional group. Conclusions: We suggest that montelukast may be effective to reduce the duration and severity of the persistent post-COVID-19 cough and further improve quality of life.
Abbreviations VAS: Cough visual analog scale; RSV: Respiratory syncytial virus; ACE: Angiotensin-converting enzyme. Authors' contributions IG was the principal investigator, formulated the idea, and wrote the first draft of discussion. AMH, MEI, and HM collected the data, formulated the results, and edited the final draft and revision. NM was responsible for methodology and statistical analysis. HA and KK were responsible for data acquisition, review search, and writing the primary draft. The authors read and approved the final manuscript. Declarations Ethics approval and consent to participate The Research Ethics Committee at the Faculty of Medicine, Aswan University, has approved the study (IRB number: aswu/469/7/2020), and all patients provided written informed consent before participation. Consent for publication The manuscript has been read and approved by all the authors. Competing interests The authors declare that they have no competing interests. Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
Assaf, Davis, Mccorkell, An analysis of the prolonged COVID-19 symptoms survey by patient-led research team, Patient Led Res
Barré, Sabatier, Annweiler, Montelukast drug may improve COVID-19 prognosis: a review of evidence, Front Pharmacol
Bisgaard, Flores-Nunez, Goh, Azimi, Halkas et al., Study of montelukast for the treatment of respiratory symptoms of post-respiratory syncytial virus bronchiolitis in children, Am J Respir Crit Care Med
Bozek, Winterstein, Montelukast's ability to fight COVID-19 infection, J Asthma, doi:10.1080/02770903.2020.1786112
Carfì, Bernabei, Landi, For the gemelli against COVID-19 post-acute care study group. Persistent symptoms in patients after acute COVID-19, JAMA, doi:10.1001/jama.2020.12603
Chen, Li, Wang, Zou, Montelukast, an anti-asthmatic drug, inhibits Zika virus infection by disrupting viral integrity, Front Microbiol
Fidan, Aydoğdu, As a potential treatment of COVID-19: montelukast, Med Hypotheses, doi:10.1016/j.mehy.2020.109828
French, Irwin, Fletcher, Evaluation of a cough-specific quality-of-life questionnaire, Chest
Galal, Hussein, Amin, Saad, Zayan et al., Determinants of persistent post-COVID-19 symptoms: value of a novel COVID-19 symptom score, Egypt J Bronchol
Huynh, Wang, Luan, In silico exploration of the molecular mechanism of clinically oriented drugs for possibly inhibiting SARS-CoV-2's main protease, J Phys Chem Lett
Peroni, Pescollderungg, Sandri, Chinellato, Boner et al., Time-effect of montelukast on protection against exerciseinduced bronchoconstriction, Respir Med
Ponsioen, Hop, Vermue, Dekhuijzen, Bohnen, Efficacy of fluticasone on cough: a randomised controlled trial, Eur Respir J
Ruiz, Nevers, Hernández, Ahnou, Brillet et al., & Ahmed-Belkacem A (2020) MK-571, a cysteinyl leukotriene receptor 1 antagonist, inhibits hepatitis C virus replication, Antimicrob Agents Chemother
Shembel, Rosen, Zullo, Gartner-Schmidt, Development and validation of the cough severity index: a severity index for chronic cough related to the upper airway, Laryngoscope, doi:10.1002/lary.23916
Spector, Tan, Effectiveness of montelukast in the treatment of cough variant asthma, Ann Allergy Asthma Immunol
Wang, Birring, Taylor, Fry, Hay et al., Montelukast for postinfectious Mohamed Hussein et al. The Egyptian Journal of Bronchology (2022) 16:52 cough in adults: a double-blind randomised placebo-controlled trial. The lancet, Respir Med
Woodcock, Mcleod, Sadeh, Smith, The efficacy of a NOP1 agonist (SCH486757) in subacute cough, Lung
Zhu, Kuang, Deng, Clinical analysis of montelukast in the treatment of post-infectious cough, China Pharmacy
{ 'indexed': {'date-parts': [[2024, 5, 4]], 'date-time': '2024-05-04T01:37:09Z', 'timestamp': 1714786629793}, 'reference-count': 20, 'publisher': 'Springer Science and Business Media LLC', 'issue': '1', 'license': [ { 'start': { 'date-parts': [[2022, 9, 15]], 'date-time': '2022-09-15T00:00:00Z', 'timestamp': 1663200000000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}, { 'start': { 'date-parts': [[2022, 9, 15]], 'date-time': '2022-09-15T00:00:00Z', 'timestamp': 1663200000000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2022, 12]]}, 'abstract': '<jats:title>Abstract</jats:title><jats:sec>\n' ' <jats:title>Background</jats:title>\n' ' <jats:p>This pilot study included 68 cases with post-COVID-19 persistent ' 'cough (&gt; 8 weeks), randomly allocated into two groups; intervention group (32 patients) ' 'received standard cough therapy, and montelukast 10 mg/day for 14 days and control group (36 ' 'patients) received only cough sedatives.</jats:p>\n' ' </jats:sec><jats:sec>\n' ' <jats:title>Results</jats:title>\n' ' <jats:p>We found a significant improvement in the number of cough ' 'paroxysms/day, cough severity visual analog scale, cough severity index and cough quality of ' 'life, shorter duration improvement, and minimal side effects in the interventional ' 'group.</jats:p>\n' ' </jats:sec><jats:sec>\n' ' <jats:title>Conclusions</jats:title>\n' ' <jats:p>We suggest that montelukast may be effective to reduce the duration ' 'and severity of the persistent post-COVID-19 cough and further improve quality of ' 'life.</jats:p>\n' ' </jats:sec>', 'DOI': '10.1186/s43168-022-00154-6', 'type': 'journal-article', 'created': {'date-parts': [[2022, 9, 15]], 'date-time': '2022-09-15T12:07:37Z', 'timestamp': 1663243657000}, 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 6, 'title': 'Value of montelukast as a potential treatment of post-COVID-19 persistent cough: a ' 'non-randomized controlled pilot study', 'prefix': '10.1186', 'volume': '16', 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-7111-2195', 'authenticated-orcid': False, 'given': 'Aliae A. R.', 'family': 'Mohamed Hussein', 'sequence': 'first', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0001-6068-5724', 'authenticated-orcid': False, 'given': 'Mohamed Eltaher A. A.', 'family': 'Ibrahim', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0001-6002-6796', 'authenticated-orcid': False, 'given': 'Hoda A.', 'family': 'Makhlouf', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0003-2949-4369', 'authenticated-orcid': False, 'given': 'Nahed A.', 'family': 'Makhlouf', 'sequence': 'additional', 'affiliation': []}, {'given': 'Howaida K.', 'family': 'Abd-Elaal', 'sequence': 'additional', 'affiliation': []}, {'given': 'Karima M. S.', 'family': 'Kholief', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0003-0844-4215', 'authenticated-orcid': False, 'given': 'Islam G.', 'family': 'Sayed', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2022, 9, 15]]}, 'reference': [ { 'issue': '6', 'key': '154_CR1', 'doi-asserted-by': 'publisher', 'first-page': '603', 'DOI': '10.1001/jama.2020.12603', 'volume': '324', 'author': 'A Carfì', 'year': '2020', 'unstructured': 'Carfì A, Bernabei R, Landi F (2020) For the gemelli against COVID-19 ' 'post-acute care study group. Persistent symptoms in patients after acute ' 'COVID-19. JAMA. 324(6):603–605. https://doi.org/10.1001/jama.2020.12603', 'journal-title': 'JAMA.'}, { 'key': '154_CR2', 'doi-asserted-by': 'crossref', 'unstructured': 'Galal I, Hussein AA, Amin MT, Saad MM, Zayan HEE, Abdelsayed M Z, ... & ' 'Hashem M. K (2021) Determinants of persistent post-COVID-19 symptoms: ' 'value of a novel COVID-19 symptom score. Egypt J Bronchol 15(1):1–8', 'DOI': '10.1186/s43168-020-00049-4'}, { 'issue': '11', 'key': '154_CR3', 'doi-asserted-by': 'publisher', 'first-page': '4413', 'DOI': '10.1021/acs.jpclett.0c00994', 'volume': '11', 'author': 'T Huynh', 'year': '2020', 'unstructured': 'Huynh T, Wang H, Luan B (2020) In silico exploration of the molecular ' 'mechanism of clinically oriented drugs for possibly inhibiting ' 'SARS-CoV-2’s main protease. J Phys Chem Lett 11(11):4413–4420', 'journal-title': 'J Phys Chem Lett'}, { 'issue': '3', 'key': '154_CR4', 'doi-asserted-by': 'publisher', 'first-page': '232', 'DOI': '10.1016/S1081-1206(10)61493-7', 'volume': '93', 'author': 'SL Spector', 'year': '2004', 'unstructured': 'Spector SL, Tan RA (2004) Effectiveness of montelukast in the treatment ' 'of cough variant asthma. Ann Allergy Asthma Immunol 93(3):232–236', 'journal-title': 'Ann Allergy Asthma Immunol'}, { 'issue': '12', 'key': '154_CR5', 'doi-asserted-by': 'publisher', 'first-page': '1790', 'DOI': '10.1016/j.rmed.2011.08.007', 'volume': '105', 'author': 'DG Peroni', 'year': '2011', 'unstructured': 'Peroni DG, Pescollderungg L, Sandri M, Chinellato I, Boner AL, ' 'Piacentini GL (2011) Time-effect of montelukast on protection against ' 'exercise-induced bronchoconstriction. Respir Med 105(12):1790–1797', 'journal-title': 'Respir Med'}, { 'key': '154_CR6', 'first-page': '2067', 'volume': '22', 'author': 'LQ Zhu', 'year': '2011', 'unstructured': 'Zhu LQ, Kuang JL, Deng ZC (2011) Clinical analysis of montelukast in the ' 'treatment of post-infectious cough. China Pharmacy 22:2067–2069', 'journal-title': 'China Pharmacy'}, { 'issue': '8', 'key': '154_CR7', 'doi-asserted-by': 'publisher', 'first-page': '854', 'DOI': '10.1164/rccm.200706-910OC', 'volume': '178', 'author': 'H Bisgaard', 'year': '2008', 'unstructured': 'Bisgaard H, Flores-Nunez A, Goh A, Azimi P, Halkas A, Malice MP, Marchal ' 'JL, Dass SB, Reiss TF, Knorr BA (2008) Study of montelukast for the ' 'treatment of respiratory symptoms of post–respiratory syncytial virus ' 'bronchiolitis in children. Am J Respir Crit Care Med 178(8):854–860', 'journal-title': 'Am J Respir Crit Care Med'}, { 'key': '154_CR8', 'doi-asserted-by': 'publisher', 'first-page': '1344', 'DOI': '10.3389/fphar.2020.01344', 'volume': '11', 'author': 'J Barré', 'year': '2020', 'unstructured': 'Barré J, Sabatier JM, Annweiler C (2020) Montelukast drug may improve ' 'COVID-19 prognosis: a review of evidence. Front Pharmacol 11:1344', 'journal-title': 'Front Pharmacol'}, { 'key': '154_CR9', 'unstructured': 'Assaf G, Davis H, McCorkell L et al (2020) An analysis of the prolonged ' 'COVID-19 symptoms survey by patient-led research team. Patient Led Res ' 'https://patientresearchcovid19.com/'}, { 'key': '154_CR10', 'volume-title': 'British Thoracic Society guidance on respiratory follow up of patients ' 'with a clinico-radiological diagnosis of COVID-19 pneumonia', 'author': 'British Thoracic Society', 'year': '2020', 'unstructured': 'British Thoracic Society (2020) British Thoracic Society guidance on ' 'respiratory follow up of patients with a clinico-radiological diagnosis ' 'of COVID-19 pneumonia ' 'https://www.brit-thoracic.org.uk/document-library/quality-improvement/covid-19/resp-follow-up-guidance-post-covid-pneumonia/'}, { 'key': '154_CR11', 'volume-title': 'Post COVID-19 patient information pack', 'author': 'Homerton University Hospital', 'year': '2020', 'unstructured': 'Homerton University Hospital (2020) Post COVID-19 patient information ' 'pack ' 'https://www.hackneycitizen.co.uk/wp-content/uploads/Post-COVID-19-information-pack-5.pdf'}, { 'key': '154_CR12', 'doi-asserted-by': 'publisher', 'unstructured': 'Shembel AC, Rosen CA, Zullo TG, Gartner-Schmidt JL (2013) Development ' 'and validation of the cough severity index: a severity index for chronic ' 'cough related to the upper airway. Laryngoscope. ' 'https://doi.org/10.1002/lary.23916', 'DOI': '10.1002/lary.23916'}, { 'key': '154_CR13', 'doi-asserted-by': 'publisher', 'first-page': '1123', 'DOI': '10.1378/chest.121.4.1123', 'volume': '121', 'author': 'C French', 'year': '2002', 'unstructured': 'French C, Irwin RS, Fletcher KE et al (2002) Evaluation of a ' 'cough-specific quality-of-life questionnaire. Chest. 121:1123–1131', 'journal-title': 'Chest.'}, { 'issue': '1', 'key': '154_CR14', 'first-page': '35', 'volume': '2', 'author': 'K Wang', 'year': '2014', 'unstructured': 'Wang K, Birring SS, Taylor K, Fry NK, Hay AD, Moore M, Jin J, Perera R, ' 'Farmer A, Little P, Harrison TG (2014) Montelukast for postinfectious ' 'cough in adults: a double-blind randomised placebo-controlled trial. The ' 'lancet. Respir Med 2(1):35–43', 'journal-title': 'Respir Med'}, { 'issue': '1', 'key': '154_CR15', 'doi-asserted-by': 'publisher', 'first-page': '147', 'DOI': '10.1183/09031936.04.00053604', 'volume': '25', 'author': 'BP Ponsioen', 'year': '2005', 'unstructured': 'Ponsioen BP, Hop WC, Vermue NA, Dekhuijzen PN, Bohnen AM (2005) Efficacy ' 'of fluticasone on cough: a randomised controlled trial. Eur Respir J ' '25(1):147–152', 'journal-title': 'Eur Respir J'}, { 'issue': '1', 'key': '154_CR16', 'doi-asserted-by': 'publisher', 'first-page': '47', 'DOI': '10.1007/s00408-009-9197-8', 'volume': '188', 'author': 'A Woodcock', 'year': '2010', 'unstructured': 'Woodcock A, McLeod RL, Sadeh J, Smith JA (2010) The efficacy of a NOP1 ' 'agonist (SCH486757) in subacute cough. Lung. 188(1):47–52', 'journal-title': 'Lung.'}, { 'key': '154_CR17', 'doi-asserted-by': 'publisher', 'unstructured': 'Bozek A, Winterstein J (2020) Montelukast’s ability to fight COVID-19 ' 'infection. J Asthma 1–2. https://doi.org/10.1080/02770903.2020.1786112', 'DOI': '10.1080/02770903.2020.1786112'}, { 'key': '154_CR18', 'doi-asserted-by': 'publisher', 'first-page': '109828', 'DOI': '10.1016/j.mehy.2020.109828', 'volume': '142', 'author': 'C Fidan', 'year': '2020', 'unstructured': 'Fidan C, Aydoğdu A (2020) As a potential treatment of COVID-19: ' 'montelukast. Med Hypotheses 142:109828. ' 'https://doi.org/10.1016/j.mehy.2020.109828 Epub 2020 May 11. PMID: ' '32416408; PMCID: PMC7211747', 'journal-title': 'Med Hypotheses'}, { 'key': '154_CR19', 'doi-asserted-by': 'publisher', 'first-page': '3079', 'DOI': '10.3389/fmicb.2019.03079', 'volume': '10', 'author': 'Y Chen', 'year': '2020', 'unstructured': 'Chen Y, Li Y, Wang X, Zou P (2020) Montelukast, an anti-asthmatic drug, ' 'inhibits Zika virus infection by disrupting viral integrity. Front ' 'Microbiol 10:3079', 'journal-title': 'Front Microbiol'}, { 'key': '154_CR20', 'doi-asserted-by': 'crossref', 'unstructured': 'Ruiz I, Nevers Q, Hernández E, Ahnou N, Brillet R, Softic L, ... & ' 'Ahmed-Belkacem A (2020) MK-571, a cysteinyl leukotriene receptor 1 ' 'antagonist, inhibits hepatitis C virus replication.\xa0Antimicrob Agents ' 'Chemother 64(6):e02078–19', 'DOI': '10.1128/AAC.02078-19'}], 'container-title': 'The Egyptian Journal of Bronchology', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://link.springer.com/content/pdf/10.1186/s43168-022-00154-6.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/article/10.1186/s43168-022-00154-6/fulltext.html', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/content/pdf/10.1186/s43168-022-00154-6.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 9, 15]], 'date-time': '2022-09-15T12:11:37Z', 'timestamp': 1663243897000}, 'score': 1, 'resource': {'primary': {'URL': 'https://ejb.springeropen.com/articles/10.1186/s43168-022-00154-6'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 9, 15]]}, 'references-count': 20, 'journal-issue': {'issue': '1', 'published-print': {'date-parts': [[2022, 12]]}}, 'alternative-id': ['154'], 'URL': 'http://dx.doi.org/10.1186/s43168-022-00154-6', 'relation': {}, 'ISSN': ['1687-8426', '2314-8551'], 'subject': [], 'container-title-short': 'Egypt J Bronchol', 'published': {'date-parts': [[2022, 9, 15]]}, 'assertion': [ { 'value': '27 June 2022', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '28 August 2022', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '15 September 2022', 'order': 3, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, {'order': 1, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Declarations'}}, { 'value': 'The Research Ethics Committee at the Faculty of Medicine, Aswan University, has ' 'approved the study (IRB number: aswu/469/7/2020), and all patients provided ' 'written informed consent before participation.', 'order': 2, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Ethics approval and consent to participate'}}, { 'value': 'The manuscript has been read and approved by all the authors.', 'order': 3, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Consent for publication'}}, { 'value': 'The authors declare that they have no competing interests.', 'order': 4, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Competing interests'}}], 'article-number': '52'}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit